

Amendments to the Claims

1-28. (Canceled)

29. (Currently amended) A method of treating cardiac hypertrophy comprising administering to a patient diagnosed with pressure overload induced $\text{PGF}_{2\alpha}$ -associated cardiac hypertrophy a therapeutically effective amount of interferon gamma ($\text{IFN-}\gamma$).

30. (Previously presented) The method of claim 29 wherein said patient is human.

31. (Canceled)

32. (Previously presented) The method of claim 30 wherein said $\text{IFN-}\gamma$ is rh $\text{IFN-}\gamma$ -1b.

33-39 (Canceled)

40. (Previously presented) The method of claim 30 wherein said $\text{IFN-}\gamma$ is administered in combination with at least one further therapeutic agent used for the treatment of cardiac hypertrophy or a heart disease resulting in cardiac hypertrophy.

41. (Previously presented) The method of claim 40 wherein said further therapeutic agent is selected from the group consisting of β -adrenergic-blocking agents, verapamil, diltiazem, and diltiazem.

42. (Previously presented) The method of claim 41 wherein said β -adrenergic-blocking agent is carvedilol, propranolol, metoprolol, timolol, alprenolol or terbutaline.

43. (Previously presented) The method of claim 40 wherein said $\text{IFN-}\gamma$ is administered in combination with an antihypertensive drug.

44. (Previously presented) The method of claim 40 wherein said IFN- γ is administered with an ACE-inhibitor.

45. (Previously presented) The method of claim 40 wherein said IFN- γ is administered with an endothelin receptor antagonist.

46. (Previously presented) The method of claim 40 wherein said IFN- γ is administered following the administration of a thrombolytic agent.

47. (Previously presented) The method of claim 46 wherein said thrombolytic agent is recombinant human tissue plasminogen activator (rht-PA).

48. (Previously presented) The method of claim 40 wherein said IFN- γ is administered following primary angioplasty for the treatment of acute myocardial infarction.

49-59. (Canceled)